Unlike other vaccine or biologic start-ups that require immediate, capital intensive investments to perform costly preclinical work such as clinical grade manufacturing and human clinical trials, PathoVax is in a unique position whereby its initial start-up investment to acquire and develop RGVax up to Phase I clinical trials is significantly discounted due to non-dilutive funding awarded by the US National Institutes of Health estimated at US$5 million. Specifically, this support was awarded to the Dr. Reinhard Kirnbauer (an inventor of the original HPV vaccines) and Dr. Richard Roden (HPV vaccine research expert), who are co-inventors of RGVax technology. These funds will support the clinical grade manufacturing scale-up, toxicology and clinical trial administrative guidance (investigational new drug application application). The significantly lower investment capital required and the NIH validation bolsters greater attractiveness to RGVax for sustained follow-on investment which ensures PathoVax’s success in this time-intensive, risky market with an extremely promising return on investment
Josh, with his team, is getting ready to change the world. Defying the odds of getting a vaccine launched, Josh has fired the imagination of venture capitalists, public health advocates, doctors, and patients to see an end to a global scourge on human health. The technology being commercialized represents a new development platform for the next generation multi-valent vaccines to combat communicable human disease. Josh is not only a solid scientist, he is a pragmatic businessperson and a compassionate leader.